

TABLE OF CONTENTS

0. Executive Summary	21
1. Introduction	23
Definitions	23
Historical aspects of biomarkers	23
Classification of biomarkers	24
Biological marker as response to therapeutic intervention	25
Pharmacokinetic/pharmacodynamics biomarkers	25
Predictive biomarkers	25
Valid biomarkers	26
Types of biomarkers	26
Genes as biomarkers	26
Proteins as biomarkers	27
<i>Proteomics</i>	<i>27</i>
DNA biomarkers.....	28
Mitochondrial DNA.....	28
<i>Mitochondrial mutations.....</i>	<i>28</i>
RNA biomarkers.....	28
<i>Transcriptomics</i>	<i>29</i>
<i>MicroRNAs.....</i>	<i>30</i>
Metabolomics	30
Glycomics	30
Single nucleotide polymorphisms	31
<i>Haplotyping.....</i>	<i>31</i>
Cell biomarkers of disease.....	32
Stem cell biomarkers.....	32
<i>Association of stem cell biomarkers with disease.....</i>	<i>32</i>
<i>Cancer stem cell biomarkers.....</i>	<i>33</i>
<i>Endoglin as a functional biomarker of stem cells</i>	<i>33</i>
<i>p75NTR as a biomarker to isolate adipose tissue-derived stem cells</i>	<i>33</i>
<i>Protein expression profile as biomarker of stem cells</i>	<i>33</i>
<i>STEMPRO® EZChek™ for analysis of biomarkers of hESCs</i>	<i>34</i>
<i>SSEA-4 as biomarker of MSCs</i>	<i>34</i>
Gaseous mediators as biomarkers of disease	34
Autoantibodies as biomarkers of autoimmune diseases	34
Comparison of various types of biomarkers	35
Biomarkers and systems biology.....	36
Systems biology approach to biomarker identification	37
Relation of biomarkers to other technologies and healthcare	37
Biomarkers and translational medicine.....	38
Limitations of use of biomarkers in healthcare	38
2. Technologies for Discovery of Biomarkers	41
Introduction.....	41
The ideal biomarker	41
Genomic technologies	41
Gene expression	41
<i>Whole genome expression array</i>	<i>42</i>
<i>Gene expression profiling on whole blood samples</i>	<i>43</i>
<i>Profiling gene expression patterns of white blood cells</i>	<i>43</i>
Tissue microarrays for study of biomarkers	43
Epigenomic technologies	44
Discovery of methylation biomarkers	44
Proteomic technologies.....	45
2D GE	46
Biomarker Amplification Filter	47
CellCarta® proteomics platform	47
Isotope-coded affinity tags.....	48
Liquid chromatography-MS/MS	48
Lucid Proteomics System	48
Magnetics beads for protein biomarker discovery	49
MASStermind™	49
Mass spectrometry	49
<i>2D PAGE and mass spectrometry</i>	<i>50</i>
<i>Imaging mass spectrometry</i>	<i>50</i>
<i>MALDI mass spectrometry for biomarker discovery</i>	<i>51</i>
<i>Quantitative tandem MS</i>	<i>52</i>

<i>Single-molecule mass spectrometry using a nanopore</i>	52
<i>Requirements for MS-based proteomic biomarker development</i>	53
Protein tomography	53
Protein biochips/microarrays and biomarkers.....	53
<i>Antibody-based biomarker discovery</i>	54
<i>Detection of biomarkers using peptide array technology</i>	54
<i>Discovery of biomarkers by MAb microarray profiling</i>	54
<i>Protein nanobiochip</i>	55
Gene expression microarray data as a source of protein biomarkers	55
Quantification of protein biomarkers	55
<i>Mass spectrometry for quantification of protein biomarkers</i>	55
<i>Real-time PCR for quantification of protein biomarkers</i>	56
<i>CyTOF for quantification of biomarkers</i>	56
Search for biomarkers in body fluids.....	56
Challenges and strategies for discovery of protein biomarkers in plasma	57
<i>3-D structure of CD38 as a biomarker</i>	58
<i>BD™ Free Flow Electrophoresis System</i>	58
<i>Isotope tags for relative and absolute quantification</i>	58
<i>Plasma protein microparticles as biomarkers</i>	59
<i>Proteome partitioning</i>	59
<i>Stable isotope tagging methods</i>	60
<i>Technology to measure both the identity and size of the biomarker</i>	60
<i>Targeted proteomic approaches</i>	61
Biomarkers in the urinary proteome	61
Peptides in body fluids and tissues as biomarkers of disease	61
<i>Analysis of peptides in bodily fluids</i>	62
<i>Serum peptidome patterns</i>	62
<i>SISCAPA method for quantitating proteins and peptides in plasma</i>	63
Comparison of proteomic profiling technologies for discovery of biomarkers	63
Verification for interlaboratory reproducibility of protein biomarkers	63
Significance of similar protein biomarkers in different tissues	64
Glycomic technologies	65
Metabolomic technologies	65
Genome-wide association studies for identification of metabolic biomarkers	66
Lipid profiling	66
Mass spectrometry-based kits for discovery of metabolic biomarkers in plasma	66
Role of metabolomics in biomarker identification and pattern recognition	67
Urinary profiling by capillary electrophoresis.....	67
Validation of biomarkers in large-scale human metabolomics studies.....	67
Lipidomics	67
Disease biomarkers in breath	68
Portable breath test for volatile organic compounds.....	68
Detection of breath biomarkers by sensation technology	69
Detection of breath biomarkers optical frequency comb spectroscopy	69
<i>Detection of breath biomarkers by infrared absorption spectroscopy</i>	69
Fluorescent indicators for biomarkers	70
Molecular imaging technologies	70
Computer tomography	70
Magnetic resonance imaging.....	71
Positron emission tomography	71
Advantages of imaging biomarkers.....	72
Monitoring in vivo gene expression by molecular imaging.....	72
Molecular imaging in vivo as a biomarker	72
Challenges and future prospects of molecular imaging	73
<i>Basic research in molecular imaging</i>	73
<i>Imaging intracellular NADH as a biomarker of disease</i>	73
<i>Devices for molecular imaging</i>	74
<i>Imaging biomarkers in clinical trials</i>	74
<i>Molecular imaging in clinical practice</i>	74
Nuclear magnetic resonance	74
Chemical derivatization to enhance biomarker detection by NMR.....	75
Fluxomics by using NMR	75
Nanobiotechnology	75
Nanomaterials for biolabeling	76
<i>Quantum dot molecular labels</i>	77
<i>Bioconjugated QDs for multiplexed profiling of biomarkers</i>	77
<i>Magnetic nanotags for multiplex detection of biomarkers</i>	78
Nanoproteomics and biomarkers	78
<i>High-field asymmetric waveform ion mobility mass spectrometry</i>	78
Nanoparticles for molecular imaging	78
Nanoparticles for discovering biomarkers	79

Nanosensors for measuring biomarkers in blood	79
Nanobiochip sensor technique for analysis of oral cancer biomarkers	80
Nucleoprotein nanodevices for detection of cancer biomarkers	80
Future prospects of application of nanobiotechnology for biomarkers	80
Bioinformatics	81
Biomarker Workflow Guide	81
Analysis of microarray data for selecting useful biomarkers	81
Role of bioinformatics in discovery of protein biomarkers	82
Role of bioinformatics in detection of cancer biomarkers	82
Biomarker databases	83
Gene networks as biomarkers	83
Role of bioinformatics in integrating various data and biomarker discovery	83
Evaluation of biomarker studies	84
3. Biomarkers and Molecular Diagnostics	85
Introduction	85
Molecular diagnostic technologies	85
Polymerase chain reaction	85
<i>Amplification</i>	<i>85</i>
<i>Target selection</i>	<i>86</i>
<i>Detection of amplified DNA</i>	<i>86</i>
<i>Limitations of PCR</i>	<i>86</i>
Real-time PCR systems	87
<i>Limitations of real-time PCR</i>	<i>87</i>
<i>Future applications of real-time qPCR</i>	<i>88</i>
<i>Real-time qPCR for quantification of circulating mtDNA</i>	<i>88</i>
Combined PCR-ELISA	88
Non-PCR methods	89
<i>Linked Linear Amplification</i>	<i>89</i>
Transcription mediated amplification	89
Rapid analysis of gene expression	89
WAVE nucleic acid fragment analysis system	90
DNA probes with conjugated minor groove binder	90
Rolling circle amplification technology	91
<i>Gene-based diagnostics through RCAT</i>	<i>91</i>
<i>RCAT-immunodiagnosics</i>	<i>92</i>
<i>RCAT-biochips</i>	<i>92</i>
<i>RCAT-pharmacogenomics</i>	<i>92</i>
Circle-to-circle amplification	92
Biochips and microarrays	93
<i>Applications of biochips/microarrays</i>	<i>93</i>
<i>Role of biochip/microarrays in discovery of biomarkers</i>	<i>94</i>
Biomarkers and high throughput molecular screening	94
Detection and expression profiling of miRNA	95
Real-time PCR for expression profiling of miRNAs	95
Real-time PCR for expression profiling of miRNAs	95
Use of LNA to explore miRNA	95
Microarrays for analysis of miRNA gene expression	96
4. Biomarkers for Drug Discovery & Development	97
Introduction	97
Biomarker technologies for drug discovery	98
Proteomics-based biomarkers for drug discovery	98
Chemoproteomics	98
<i>Activity-based chemical proteomics</i>	<i>98</i>
Transcriptomics for drug discovery	99
AvalonRx® drug discovery platform	99
Metabolomics for drug discovery	99
Biomarkers and drug safety	100
Biomarkers of adverse drug reactions	100
Applications of biomarkers in drug safety studies	101
Genomic technologies for toxicology biomarkers	101
Proteomic technologies for toxicology biomarkers	102
Metabonomic technologies for toxicology biomarkers	102
Integration of genomic and metabonomic data to develop toxicity biomarkers	102
Toxicology studies based on biomarkers	103
<i>Biomarkers of hepatotoxicity</i>	<i>104</i>
<i>Biomarkers of nephrotoxicity</i>	<i>105</i>
<i>Cardiotoxicity</i>	<i>106</i>
<i>Neurotoxicity</i>	<i>107</i>
Applications of biomarkers for drug development	107

Application of metabonomics/metabolomics for drug development	107
Role of pharmacokinetic/pharmacodynamic biomarkers in drug development	108
Molecular imaging as a biomarker in drug development	109
<i>Molecular imaging in preclinical studies</i>	109
<i>Molecular imaging in clinical trials</i>	110
<i>Prospects of molecular imaging in drug discovery and development</i>	111
Biomarkers in clinical trials	111
<i>NIH recommendations on the use of biomarkers in clinical trials</i>	112
<i>Advantages of biomarkers for drug development</i>	113
<i>Limitations and problems with use of biomarkers in clinical trials</i>	113
Application of biomarkers by the pharmaceutical companies	114
Use of biomarkers in relation to stage of drug discovery and development	115
Drug development in cardiovascular disorders	115
Drug development in neurological disorders	115
Future prospects of biomarker-based drug development	116
<i>The Biomarker Alliance</i>	116
<i>Molecular Libraries and Imaging Roadmap of NIH</i>	117
<i>Biomarkers Consortium</i>	117
<i>Pharmacogenomic biomarker information in drug labels</i>	118
<i>Concluding remarks on the future trends in biomarker development</i>	119

5. Role of Biomarkers in Healthcare..... 121

Introduction	121
Biomarkers of inflammation	121
ESR and CRP as biomarkers of inflammation	122
Biomarkers of oxidative stress	122
1,4-dihydroxynonane-mercaptopic acid	122
Oxidative DNA damage	123
Proteins as biomarkers of oxidative stress in diseases	123
Testing for oxidative stress	123
Biomarkers in metabolic disorders	123
Biomarkers of acute intermittent porphyria	123
Liver X receptors	124
Biomarkers of diabetes mellitus	124
<i>Biomarkers of hyperglycemia</i>	125
<i>Biomarkers of diabetes-associated oxidative stress</i>	125
<i>Biomarkers of inflammation associated with diabetes</i>	126
<i>Biomarkers of renal complications in diabetes mellitus type 2</i>	126
<i>Biomarkers of diabetes</i>	126
<i>Glycosylated hemoglobin in diabetes mellitus</i>	126
<i>Glycated albumin as a biomarker of diabetes mellitus</i>	127
<i>Lack of C-peptide as biomarker of complications of diabetes type 1</i>	127
<i>Serum retinol binding protein 4 as biomarker of insulin resistance</i>	127
Biomarkers of metabolic syndrome	128
<i>Adiponectin</i>	128
Biomarkers in immune disorders	129
Biomarkers relevant to organ transplantation	129
<i>Biomarkers of graft versus host disease</i>	129
<i>Biomarkers of renal allograft failure</i>	130
<i>Biomarkers of renal transplant tolerance</i>	131
<i>Biomarkers of lung transplant rejection</i>	132
Systemic lupus erythematosus	132
<i>Current management and need for biomarkers</i>	132
<i>Role of collaborative efforts and databases of SLE biomarkers</i>	133
<i>C4d-bearing reticulocytes</i>	133
<i>Adiponectin</i>	133
<i>CB-CAPS</i>	133
<i>HMGB1</i>	134
<i>Genetic loci of SLE</i>	134
<i>Epigenetic biomarkers of SLE</i>	134
Biomarkers of musculoskeletal disorders	134
Biomarkers of rheumatoid arthritis	135
<i>Circulating cytokines in RA</i>	135
<i>miRNA biomarkers in RA</i>	135
<i>Serum CRP in RA</i>	136
<i>Assays for biomarkers of RA</i>	136
Biomarkers of spondylarthritis	136
Biomarkers of osteoarthritis	137
Biomarkers of osteoporosis	138
<i>Dual x-ray absorptiometry</i>	139
<i>Bone imaging with quantitative CT and MRI</i>	139

<i>Assays for detection of biomarkers of osteoporosis</i>	139
Biomarkers of osteonecrosis	139
<i>Osteonecrosis in Gaucher's disease</i>	139
Biomarkers of infectious diseases	139
Application of proteomics for discovering biomarkers of infections	141
Chemokines as biomarkers of infection	141
Circulating CPS-1 as biomarkers of organ damage in sepsis	141
CoQ10 level reduction in septic shock	142
Endotoxin as biomarker of infection	142
Nitric oxide as a biomarker of sepsis	142
Procalcitonin as a guide to antibiotic therapy in infections	143
Soluble urokinase plasminogen activator receptor	144
Systemic inflammatory response syndrome	144
Tuberculosis	144
<i>Conventional diagnosis of tuberculosis</i>	145
<i>Molecular diagnostics for tuberculosis</i>	145
<i>Biomarkers for tuberculosis</i>	146
<i>Biomarkers of pulmonary tuberculosis in the breath</i>	146
Biomarkers of viral infections	146
<i>Viral hepatitis</i>	147
<i>Biomarkers of SARS</i>	149
<i>Biomarkers of HIV</i>	149
Biomarkers in parasitic infections	150
<i>Role of biomarkers in malaria</i>	150
<i>Identification of biomarkers in Schistosomiasis infections</i>	151
Biomarkers of liver disease	151
Breath biomarkers of liver disease	151
Biomarkers of viral hepatitis B and C	152
Biomarkers of liver injury	153
Biomarkers of liver cirrhosis	153
FibroMax	153
Biomarkers of pancreatitis	153
Biomarkers of renal disease	154
Biomarkers of lupus nephritis	154
Biomarkers of diabetic nephropathy	154
Cystatin C as biomarker of glomerular filtration rate (GFR)	155
Estimated GFR and albuminuria as biomarkers of chronic kidney disease	155
Proteomic biomarkers of acute kidney injury	155
Biomarkers of pulmonary diseases	156
Biomarkers of oxidative stress in lung diseases	156
Biomarkers of acute lung injury and respiratory distress syndrome	157
<i>Cytokine/chemokine biomarkers of SARS</i>	157
<i>Plasma biomarkers related to inflammation</i>	157
<i>Urinary NO as biomarker</i>	157
Biomarkers of interstitial lung disease	158
<i>Pulmonary surfactant proteins as biomarkers for lung diseases</i>	158
<i>Serum KL-6 as biomarker of interstitial lung disease</i>	158
Biomarkers of chronic obstructive pulmonary disease	158
<i>Alpha1-antitrypsin gene polymorphisms predisposing to emphysema</i>	159
<i>BNP as a biomarker of chronic pulmonary disease</i>	159
<i>Chromagranin A (CgA) as biomarker of airway obstruction in smokers</i>	159
<i>Gene expression profile in peripheral blood of patients with COPD</i>	159
<i>Increased expression of PIGF as a biomarker of COPD</i>	159
Biomarkers of asthma	160
<i>Biomarker for rhinovirus-induced asthma exacerbation</i>	160
<i>Biomarkers for predicting response to corticosteroid therapy</i>	160
<i>Comparison of biomarkers of asthma and COPD</i>	160
<i>Cytokines as biomarkers of asthma severity</i>	161
<i>Exhaled NO as a biomarker of asthma</i>	161
<i>Endothelin-1 in exhaled breath as biomarker of asthma</i>	162
<i>IgE as guide to dosing of omalizumab for asthma</i>	162
<i>Periostin as a biomarker for treatment of asthma with lebrikizumab</i>	162
Biomarkers for cystic fibrosis	163
Biomarkers of pulmonary embolism	163
<i>D-dimer as biomarker of thromboembolism</i>	163
<i>BNP and cTnT as biomarkers of outcome in pulmonary embolism</i>	164
Biomarkers in gynecology and obstetrics	164
Biomarkers of menopause	164
Biomarkers of premenstrual dysphoric disorder	165
Biomarkers of endometriosis	165
Biomarkers for preeclampsia	166

<i>Protein biomarker of preeclampsia in urine</i>	166
<i>Protein biomarkers of preeclampsia in CSF</i>	166
<i>Protein HtrA1 as biomarker for preeclampsia</i>	167
<i>sFlt1 and soluble endoglin as biomarkers of preeclampsia</i>	167
<i>RNA biomarkers</i>	168
Biomarkers of premature birth.....	168
Biomarkers of oxidative stress in complicated pregnancies.....	169
Fetal biomarkers in maternal blood.....	169
Biomarkers for genetic disorders.....	169
Biomarkers for Down's syndrome.....	169
Biomarkers for muscular dystrophy.....	170
Biomarkers of phenylketonuria.....	170
Genetic biomarkers for psoriasis.....	171
Biomarkers of lysosomal storage disorders.....	171
Biomarkers of aging.....	172
Effect of calorie restriction on biomarkers of longevity.....	174
Genes as biomarkers of aging.....	174
<i>Mitochondrial mutations as biomarkers of aging</i>	174
<i>Telomere attrition as aging biomarker</i>	174
<i>Gene variants as determinants of biological age</i>	175
<i>Genetic signatures of longevity</i>	175
Low serum thyroid hormone level as biomarker of longevity.....	175
Role of bioinformatics in search for biomarkers of aging.....	176
Study of biomarkers of aging in a genetically homogeneous population.....	176
Biomarkers of miscellaneous disorders.....	176
Biomarkers of inflammatory bowel disease.....	176
Biomarkers of erectile dysfunction.....	177
Biomarkers of fever.....	178
Biomarkers of heat stroke.....	178
Biomarkers of radiation injury.....	178
Biomarkers common to multiple diseases.....	179
Nasal nitric oxide as a biomarker of response to rhinosinusitis therapy.....	179
Biomarkers and nutrition.....	179
Biomarkers in nutritional epidemiology.....	179
Biomarkers of nutritional status.....	180
Biomarkers of branched chain amino acid status.....	180
Biomarkers of caloric restriction.....	180
Biomarkers of malnutrition.....	181
Proteomic biomarkers and nutrition.....	181
Vitamin deficiency as biomarker of disease.....	181
<i>Vitamin D as a biomarker of disease</i>	181
<i>Vitamin B12 deficiency</i>	182
Biomarkers of gene-environmental interactions in human disease.....	183
6. Biomarkers of Cancer.....	185
Introduction.....	185
The ideal biomarker for cancer.....	185
Single vs multiple biomarkers of cancer.....	186
Types of cancer biomarkers.....	186
HER3 as biomarker of cancer.....	187
DNA repair biomarkers.....	187
miRNAs as biomarkers in cancer.....	187
<i>Circulating miRNAs for cancer detection</i>	189
<i>Diagnostic value of miRNA in cancer</i>	189
Biomarkers of epigenetic gene silencing in cancer.....	189
Immunologic biomarkers of cancer.....	190
Molecular diagnostic techniques for cancer.....	190
Technologies for detection of cancer biomarkers.....	191
Genomic technologies for cancer biomarkers.....	191
<i>Cold-PCR</i>	191
<i>Genome analysis at the molecular level</i>	192
<i>Sequencing-based approaches for detection of cancer biomarkers</i>	192
<i>Early detection of tumor suppressor gene mutations</i>	192
<i>Biomarkers of PTEN tumor suppressor gene status</i>	193
<i>HAAH as a biomarker for cancer</i>	193
<i>KRAS as a biomarker of cancer</i>	194
<i>Telomerase as a biomarker of cancer</i>	194
<i>Digital karyotyping for cancer biomarkers</i>	194
<i>LigAmp for detection of gene mutations in cancer</i>	195
<i>Mitochondrial DNA as a cancer biomarker</i>	195
Tissue microarrays for study of cancer biomarkers.....	195

Molecular fingerprinting of cancer	196
Biomarkers of inflammation in cancer	197
Proteomic technologies for detecting biomarkers of cancer	197
2D PAGE	198
<i>Antibody-based detection of protein biomarkers</i>	198
<i>Aptamer-based molecular probes for cancer biomarker discovery</i>	199
<i>Cancer immunomics to identify autoantibody signatures</i>	199
<i>Desorption electrospray ionization for detection of cancer biomarkers</i>	200
<i>Detection of circulating nucleosomes in serum of cancer patients</i>	200
<i>Detection of tumor markers with ProteinChip technology</i>	200
<i>eTag assay system for cancer biomarkers</i>	201
<i>Glycoprotein biomarkers of cancer</i>	201
<i>HER-2/neu oncoprotein as biomarkers for cancer</i>	202
<i>Humoral proteomics</i>	202
<i>Laser capture microdissection</i>	202
<i>Membrane-type serine protease-1</i>	203
<i>Phage display technology</i>	203
<i>Proteomic analysis of cancer cell mitochondria</i>	203
<i>Proteomic technologies for detection of autoimmune biomarkers</i>	204
<i>SELDI-TOF MS</i>	204
<i>Serum proteome analysis for early detection of cancer</i>	204
<i>Triple-quadrupole MS for detection of mutant proteins</i>	205
<i>Targeted MS for validation of cancer biomarkers in plasma</i>	205
<i>Tissue proteomics for discovery of cancer biomarkers</i>	205
Metabolomic biomarkers of cancer	205
<i>Choline phospholipid biomarkers of cancer</i>	206
<i>Hypoxia-inducible factor-1</i>	206
<i>Detection of drug resistance in cancer by metabolic profiling</i>	207
Epitomics for the early detection of cancer	207
Detection of biomarkers of DNA methylation	207
<i>PCR with bisulfite for detecting DNA methylation biomarkers in cancer</i>	209
<i>MDScan™ microarray technology</i>	210
<i>Rubicon MethylPlex technology</i>	210
<i>Epigenomics Marker Machine for DNA methylation biomarkers</i>	210
<i>Sequenom's integrated genetic analysis platform</i>	211
<i>Histone deacetylase</i>	211
<i>Mucins as epigenetic biomarkers in epithelial cancers</i>	211
Nanobiotechnology for early detection of cancer to improve treatment	212
Selective expression of biomarkers by cancer compared with normal tissues	212
Ultrasound radiation to enhance release of a tumor biomarker.....	212
In vivo imaging of cancer biomarkers	213
<i>Computer tomography</i>	213
<i>Optical systems for in vivo molecular imaging of cancer</i>	213
<i>Positron emission tomography</i>	213
<i>Imaging of tumor oxygenation and microvascular permeability by MRI</i>	214
<i>Xenon-enhanced MRI</i>	214
Kallikrein gene family and cancer biomarkers	214
Circulating cancer cells in blood as biomarkers of cancer.....	215
Applications of cancer biomarkers	216
Use of biomarkers for cancer classification	216
<i>Cancer classification using microarrays</i>	216
<i>Proteomic classification of cancer</i>	216
Use of biomarkers for early detection of cancer.....	216
Applications of biomarkers for cancer diagnosis	217
<i>Methylated DNA sequences as cancer biomarkers</i>	217
<i>MicroRNA expression profiling for diagnosis of human cancers</i>	218
<i>MUC4 as a diagnostic biomarker in cancer</i>	218
Applications of biomarkers for cancer diagnosis and therapy	218
<i>Asparagine synthetase as biomarker for therapy with L-asparaginase</i>	219
<i>Peptide-based agents for targeting cancer biomarkers</i>	219
Biomarkers for assessing efficacy of cancer therapy	220
<i>ERCC1-XPF expression as a biomarker of response to chemotherapy</i>	220
<i>P53 expression level as biomarker of efficacy of cancer gene therapy</i>	220
Biomarkers of angiogenesis for developing antiangiogenic therapy	220
<i>Biomarkers of response to antiangiogenic agents</i>	221
<i>Circulating endothelial cells as targets for antiangiogenic drugs</i>	221
<i>Imaging biomarkers for evaluation of antiangiogenic agents</i>	221
<i>Tumor endothelial markers</i>	222
<i>VEGF signaling inhibitors as biomarkers</i>	222
<i>VEGF-PET imaging for analysis of angiogenic changes within a tumor</i>	223
Biomarkers of prognosis in cancer treatment	223

Biomarkers of drug resistance in cancer	223
<i>A systems approach to biomarkers of innate drug resistance</i>	224
<i>Epithelial membrane protein-1 as a biomarker of gefitinib resistance</i>	224
<i>Methylation biomarkers of drug resistance in cancer</i>	224
<i>STAT3 and resistance to cisplatin</i>	225
Biomarkers of radiation therapy for cancer	225
Role of biomarkers in drug development in oncology	225
Molecular imaging of tumor as a guide to drug development	226
<i>Use of PET to assess response to anticancer drugs</i>	227
<i>Use of MRI to assess response to anticancer drugs</i>	227
Biomarkers in plucked hair for assessing cancer therapy	227
Molecular targets of anticancer drugs as biomarkers	228
Safety biomarkers in oncology studies	228
Role of biomarkers in phase I clinical trials of anticancer drugs	228
Biomarkers according to location/type of cancer	229
Bladder cancer biomarkers	229
<i>Detection of FGFR3 mutations in urine for diagnosis of bladder cancer</i>	229
<i>NMP22 BladderChek</i>	229
<i>Urinary telomerase as biomarker for detection of bladder cancer</i>	230
<i>Concluding remarks about biomarkers of urinary cancer</i>	230
Brain tumor biomarkers	230
<i>14-3-3zeta positive expression as a prognostic biomarker for GBM</i>	231
<i>Biomarkers to predict response to EGFR inhibitors</i>	231
<i>CD133 as biomarker of resistance to radiotherapy</i>	231
<i>Circulating microvesicles as biomarkers</i>	232
<i>CSF protein profiling</i>	232
<i>CSF attractin as a biomarker of malignant astrocytoma</i>	232
<i>Methylation profiling of brain tumors</i>	232
<i>Metabolite biomarkers of brain tumors</i>	233
<i>miRNAs as biomarkers of brain tumors</i>	234
<i>MRI biomarker for response of brain tumor to therapy</i>	234
<i>Multigene predictor of outcome in GBM</i>	234
<i>Neuroimaging biomarkers combined with DNA microarray analysis</i>	235
<i>Receptor protein tyrosine phosphatase β as biomarker of gliomas</i>	235
<i>Serum protein fingerprinting</i>	235
<i>VEGF-R2 as biomarker of angiogenesis in brain tumors</i>	236
Bone tumor biomarkers	236
<i>Cytogenetics for the study of bone and soft tissue tumors</i>	236
<i>Biomarkers of Ewing's tumors</i>	236
<i>Role of biomarkers in the diagnosis of bone tumors</i>	237
Breast cancer biomarkers	237
<i>Autoantibody biomarkers of breast cancer</i>	238
<i>Biomarkers of breast cancer in breath</i>	239
<i>Biomarkers for breast cancer in nipple aspiration fluid</i>	239
<i>Circulating nucleic acid biomarkers of breast cancer</i>	239
<i>Flow cytometry for quantification of biomarker expression patterns</i>	239
<i>Plasma proteomics for biomarkers of breast cancer</i>	240
<i>Quantitative realtime PCR assays for biomarker validation</i>	240
<i>Cdk6 as a biomarker of breast cancer</i>	241
<i>Centromere protein-F</i>	241
<i>Carbonic anhydrase IX</i>	241
<i>COX-2 as a biomarker of breast cancer</i>	242
<i>Glycomic biomarkers of breast cancer</i>	242
<i>HER-2/neu oncoprotein</i>	242
<i>High mobility group protein A2</i>	244
<i>Hypermethylated genes as biomarkers of metastatic breast cancer</i>	244
<i>Lipocalin 2 as biomarker of breast cancer progression</i>	244
<i>Long intervening non-coding RNAs</i>	245
<i>Mammaglobin</i>	245
<i>miRNA biomarkers of breast cancer</i>	245
<i>p27 expression as biomarker for survival after chemotherapy</i>	246
<i>Podocalyxin</i>	246
<i>Progranulin as a biomarker of breast cancer</i>	247
<i>Proliferating cell nuclear antigen</i>	247
<i>Protein kinase C as a predictive biomarker of metastatic breast cancer</i>	247
<i>Retinoblastoma tumor suppressor gene as a biomarker</i>	247
<i>Riboflavin carrier protein</i>	248
<i>Risk of invasive cancer after diagnosis of ductal carcinoma in situ</i>	248
<i>Serum CA 15-3 as biomarker of prognosis in advanced breast cancer</i>	249
<i>Suppressor of deltex protein</i>	249
<i>Tumor microenvironment as biomarker of metastasis in breast cancer</i>	249

<i>Type III TGF-β receptor as regulator of cancer progression</i>	249
<i>Diagnostic tests based on breast cancer genes</i>	250
<i>Prognostic role of breast cancer genes</i>	251
<i>Protein biomarkers for breast cancer prevention</i>	252
<i>Biomarkers to evaluate efficacy of chemoprevention</i>	252
<i>Biomarkers of response to chemotherapy of breast cancer</i>	252
<i>Concluding remarks and future prospects of breast cancer biomarkers</i>	253
Cervical cancer biomarkers	253
Gastrointestinal cancer biomarkers.....	255
<i>Esophageal cancer biomarkers</i>	255
<i>Gastric cancer biomarkers</i>	255
<i>Colorectal cancer biomarkers</i>	256
Head and neck cancer	261
Leukemia biomarkers	262
<i>Chromosome translocations in leukemias</i>	262
<i>DNA methylation biomarkers in leukemia</i>	263
<i>Gene mutations as biomarkers in leukemia</i>	263
<i>Molecular diagnostic techniques for leukemia</i>	263
<i>Proteomic technologies for discovering biomarkers of leukemia</i>	264
<i>Biomarkers of chronic lymphocytic leukemia</i>	264
<i>Biomarkers of chronic myeloid leukemia</i>	265
<i>Biomarkers of drug resistance in leukemia</i>	265
<i>Biomarkers of myelodysplastic syndromes</i>	266
Lymphoma biomarkers	266
Liver cancer biomarkers.....	266
Lung cancer biomarkers.....	267
<i>Autoantibodies as biomarkers in lung cancer</i>	268
<i>Biomarkers associated with neuroendocrine differentiation in NSCLC</i>	269
<i>Biomarkers of chronic inflammation in lung cancer</i>	269
<i>Biomarkers for predicting sensitivity to chemotherapy in lung cancer</i>	269
<i>Biomarkers for prediction of sensitivity to EGFR inhibitors</i>	270
<i>Circulating tumor cells as biomarkers</i>	271
<i>Gene expression profiling for biomarkers of lung cancer</i>	271
<i>Methylation biomarkers of lung cancer</i>	272
<i>miRNA biomarkers in lung cancer</i>	272
<i>Proteomic biomarkers in exhaled breath condensate</i>	273
<i>Serum protein biomarkers of lung cancer</i>	273
<i>tNOX as biomarker of lung cancer</i>	274
<i>Tumor-derived DNA and RNA markers in blood</i>	274
<i>Volatile organic compounds in the exhaled breath</i>	274
Malignant pleural mesothelioma.....	275
Melanoma biomarkers	275
Nasopharyngeal carcinoma biomarkers	277
<i>Proteomic biomarkers of nasopharyngeal cancer</i>	278
<i>miRNA biomarkers of nasopharyngeal carcinoma</i>	278
Oral cancer biomarkers.....	278
Ovarian cancer biomarkers.....	279
<i>Epitomics approach for ovarian cancer biomarkers in serum</i>	280
<i>Gene expression studies in ovarian cancer</i>	281
<i>HE4 protein in urine as a biomarker for ovarian cancer</i>	281
<i>HtrA1 as a biomarker of response to chemotherapy in ovarian cancer</i>	281
<i>Mutation of genes in ovarian cancer</i>	282
<i>Serum biomarkers of ovarian cancer prognosis</i>	282
<i>Serum albumin-associated peptides and proteins</i>	282
<i>Multiplex assays for biomarkers of ovarian cancer</i>	283
<i>Concluding remarks on biomarker-based tests of ovarian cancer</i>	284
Pancreatic cancer biomarkers	284
<i>Discovery and validation of pancreatic cancer biomarkers</i>	285
<i>Cancer stem cells as biomarkers of pancreatic cancer</i>	285
<i>Histone modifications used as biomarkers in pancreatic cancer</i>	285
<i>miRNA biomarkers of pancreatic cancer</i>	286
<i>Parathyroid cancer biomarkers</i>	287
<i>Proteomic biomarkers of pancreatic cancer</i>	287
Prostate cancer.....	288
<i>Adipose tissue-derived biomarkers of obesity-related prostate cancer</i>	289
<i>B7-H3 as biomarker of prostate cancer</i>	289
<i>Cancer genetics-guided biomarker signatures of prostate cancer</i>	289
<i>Detection of prostate cancer biomarkers in urine</i>	290
<i>Detection of prostatic intraepithelial neoplasia</i>	291
<i>Epigenetic biomarkers of prostate cancer</i>	291
<i>Gene expression analysis of prostate cancer</i>	291

Genetic biomarkers of prostate cancer	292
Huntingtin Interacting Protein 1 overexpression in prostate cancer.....	292
Id proteins expression in prostate cancer	293
Identification of prostate cancer mRNA biomarkers.....	293
Integrative genomic and proteomic profiling of prostate cancer.....	293
LCM for diagnosis of prostate cancer	293
Loss of p27 as predictor of recurrence of prostate cancer	294
Microarray for diagnosis of prostate cancer.....	294
miRNA biomarkers of prostate cancer	294
Prostate cancer biomarkers in semen	295
PSA as biomarker of prostate cancer	295
ProPSA as biomarker of prostate cancer.....	296
Prostate Health Index.....	296
Prostasomes in blood as biomarker of prostate cancer	296
PSMA as biomarker of prostate cancer	296
Sarcosine as a metabolic biomarker of prostate cancer	297
Serum HAAH as biomarker of prostate cancer.....	297
Silenced CDH13 gene as a biomarker of cancer.....	297
Serum-protein fingerprinting	297
Tests for prostate cancer based on genetic dislocations.....	298
Concluding remarks on biomarkers of prostate cancer	298
Renal cancer biomarkers.....	298
Gene expression profile of RCC for biomarkers.....	299
miRNA biomarkers of renal cancer.....	299
Use of proteomics for detection of RCC biomarkers	299
Use of RCC biomarkers for prognosis and therapy	300
Thyroid cancer biomarkers	300
Detection of BRAF mutation.....	301
Gene expression biomarkers of thyroid cancer.....	301
Multiple endocrine neoplasia type 2B as risk factor for thyroid cancer	301
miRNA biomarkers of thyroid cancer.....	302
Biochemical biomarkers of thyroid cancer.....	302
Role of the NCI in molecular diagnosis of cancer	302
The Cancer Genome Anatomy Project	302
Molecular profiling of cancer	303
Cancer Genome Atlas	303
Cancer Genetic Markers of Susceptibility Project	304
Oncology Biomarker Qualification Initiative	304
Role of NCI in cancer biomarker development and validation	304
Projects for cancer biomarker research in Europe	306
COBRED project.....	306
COLTHERES consortium	306
PREDICT Consortium	306
Future prospects for cancer biomarkers	307
Cancer biomarker research at academic institutions	307
Future prospects and challenges in the discovery of cancer biomarkers.....	307
7. Biomarkers of Disorders of the Nervous System.....	309
Introduction.....	309
Discovery of biomarkers for neurological disorders	309
Biomarker identification in the CSF using proteomics	310
Biomarker identification in the CSF using lipidomics	310
Cerebral microdialysis for the study of biomarkers of cerebral metabolism	311
Detection of protein biomarkers of CNS disorders in the blood	311
Brain imaging for detection of biomarkers	311
Biomarkers of the aging brain.....	312
Cellular biomarker of aging of the brain	312
CSF F2-isoprostanes as biomarker of aging brain	312
Protein aggregation as a biomarker of aging brain.....	312
Data mining for biomarkers of neurological disorders	313
Antibodies as biomarkers in disorders of the nervous system	313
Biomarkers of neural regeneration	313
Biomarkers of disruption of blood-brain barrier.....	314
Biomarkers of neurotoxicity.....	314
Glial fibrillary acidic protein as biomarker of neurotoxicity	315
Single-stranded DNA as a biomarker of neuronal apoptosis	315
Biomarkers of neurogenetic disorders	315
Charcot-Marie Tooth disease	316
Duchenne and Becker muscular dystrophy	316
Fragile X syndrome	317
Hereditary neuropathy with liability to pressure palsies.....	317

Hereditary metabolic storage disorders with neurologic manifestations	318
<i>Gaucher disease</i>	318
<i>Pompe's disease</i>	318
Mitochondrial disorders affecting the nervous system	318
Spinal muscular atrophy	319
Biomarkers of neurodegenerative disorders	319
Biomarkers of Alzheimer's disease	320
The ideal biomarker for AD.....	322
Methods for determining biomarkers of AD	322
<i>Gene expression patterns in AD</i>	322
<i>Magnetic resonance spectroscopy in AD</i>	323
<i>MRI for biomarkers of AD</i>	323
<i>Nanotechnology to measure Aβ-derived diffusible ligands</i>	325
<i>PET scanning for biomarkers of AD</i>	325
<i>Radioiodinated cloquinol as a biomarker for Aβ</i>	327
<i>Simultaneous measurement of several biomarkers for AD</i>	327
<i>Targeting of chemokine receptor as biomarker for brain imaging</i>	328
Biomarkers of AD in CSF	328
<i>CSF sulfatide as a biomarker for AD</i>	328
<i>CSF Reelin as biomarker of AD</i>	328
<i>Glycerophosphocholine as CSF biomarker in AD</i>	329
<i>Monitoring of synthesis and clearance rates of Aβ in the CSF</i>	329
<i>Protein biomarkers of AD in CSF</i>	329
<i>Tau proteins in CSF</i>	331
<i>Tests for the detection of Aβ in CSF</i>	331
<i>Tests combining CSF tau and Aβ</i>	332
Blood biomarkers of AD	333
<i>A serum protein-based algorithm for the detection of AD</i>	333
<i>Amyloid precursor protein</i>	333
<i>Detection of aggregated misfolded proteins in the blood</i>	333
<i>Lymphocyte Proliferation Test</i>	334
<i>Plasma protein biomarkers of AD</i>	334
<i>Protein kinase C in red blood cells</i>	335
Urine tests for AD	335
A biomarker-based skin test for AD	335
Salivary biomarkers of AD	336
Applications of biomarkers of AD.....	336
<i>Genetic tests for AD</i>	336
<i>Plasma biomarkers of drug response in AD</i>	336
<i>PredictAD project</i>	337
<i>TOMM40 gene and risk of AD</i>	337
<i>Use of biomarkers to predict AD in patients with MCI</i>	337
Concluding remarks about biomarkers for AD	338
Biomarkers of Parkinson's disease.....	338
Biomarkers of PD based on gene expression in blood.....	339
Cardiac denervation as a biomarker of PD	339
Imaging biomarkers of PD.....	340
Metabolic brain networks as biomarkers.....	340
Metabonomic biomarker profile for diagnosis and monitoring of PD	341
Protein biomarkers of PD	341
Serum vitamin D as a biomarker of PD	341
Future prospects for biomarkers of PD	342
Biomarkers of Huntington's disease.....	342
Quantitative MRI measurement of brain atrophy as biomarker of HD	343
Biomarkers of Wilson's disease.....	344
Biomarkers of amyotrophic lateral sclerosis	344
Biomarkers of neuroinflammation in ALS	345
Detection of ALS biomarkers in blood vs CSF.....	345
Ideal biomarker of ALS	345
Imaging biomarkers of ALS	346
Metabolomic biomarkers of ALS	346
Proteomic biomarkers of ALS	346
Future prospects of biomarkers of ALS.....	347
Biomarkers of dementia in HIV-1-infected patients	347
Biomarkers of prion diseases	347
14-3-3 protein and tTau/P-Tau ratio.....	348
Bioluminescence imaging as a surrogate biomarker of prion infectivity	348
Biomarkers of multiple sclerosis	348
Antibodies in multiple sclerosis	349
<i>Antibodies to galactocerebroside</i>	350
<i>Antibodies to myelin oligodendrocyte glycoprotein</i>	350

<i>Detecting autoantibodies in multiple sclerosis</i>	350
CSF Cystatin C as a biomarker of multiple sclerosis	350
T cells as biomarkers of multiple sclerosis	351
Matrix metalloproteinases as biomarkers in multiple sclerosis	351
Gelsolin as a biomarker of multiple sclerosis	351
Gene expression profiling of biomarkers in multiple sclerosis	352
Serum proteomic pattern analysis in multiple sclerosis	352
Brain imaging biomarkers of multiple sclerosis	352
<i>MRI biomarkers of multiple sclerosis</i>	352
<i>Myelin imaging by PET</i>	353
Biomarkers of response to therapy of multiple sclerosis	353
<i>DNA motifs in the blood as biomarkers of response to treatment</i>	353
Concluding remarks and future perspective for biomarkers of multiple sclerosis	354
Biomarkers of cerebrovascular disorders	354
Biomarkers of stroke	354
<i>Brain natriuretic peptide as a biomarker for cardioembolic stroke</i>	356
<i>Brain lactate and N-acetylaspartate as biomarkers of stroke</i>	356
<i>CRP as biomarker of risk of stroke</i>	356
<i>CSF biomarkers in acute stroke</i>	357
<i>Gene expression in blood following ischemic stroke</i>	357
<i>Intercellular adhesion molecule 1 as biomarker of ischemic stroke</i>	357
<i>Lp-PLA2 and CRP as biomarkers for stroke</i>	358
<i>Matrix metalloproteinase-9</i>	358
<i>Neuroserpin polymorphisms as a biomarker of stroke</i>	358
<i>NMDA receptors as biomarkers of excitotoxicity in stroke</i>	358
<i>Nucleosomes as biomarkers of stroke</i>	359
<i>PARK7 and nucleoside diphosphate kinase A as biomarkers of stroke</i>	359
<i>Visinin-like protein 1</i>	359
<i>Biomarker panel for stroke</i>	359
<i>Future prospects for biomarkers of stroke</i>	360
Biomarkers of cerebral vasospasm	360
Biomarkers of intracerebral hemorrhage	361
Biomarkers of hypoxic brain damage	361
D-dimer as a biomarker of cerebral venous thrombosis	362
Biomarkers of traumatic brain injury	362
Technologies for identification of biomarkers of TBI	363
<i>Proteomic technologies for biomarkers of TBI</i>	363
<i>Cerebral microdialysis for study of biomarkers of TBI</i>	364
Biomarkers of TBI	364
<i>C-tau as biomarker of TBI</i>	364
<i>Diffusion tensor imaging in TBI</i>	365
<i>Hyperphosphorylated axonal neurofilament protein</i>	365
<i>IL-6 and nerve growth factor as biomarkers of TBI</i>	365
<i>Serum S100B as biomarker of TBI</i>	366
<i>Ubiquitin C-terminal Hydrolase-L1</i>	366
Biomarkers of inflicted TBI in infants	366
Clinical applications of biomarkers of TBI	366
Biomarkers of CNS infections	367
Biomarkers of CNS HIV infection	367
Biomarkers of bacterial meningitis	368
Biomarkers of epilepsy	368
Genetic epilepsies	369
Biochemical markers of epilepsy	369
Imaging biomarkers of epilepsy	369
Biomarkers of normal pressure hydrocephalus	369
Biomarkers of retinal disorders	370
Biomarkers of age-related macular degeneration	370
Biomarkers of sleep disorders	371
Biomarker of excessive daytime sleepiness	371
Biomarkers of obstructive sleep apnea	371
Biomarkers of restless legs syndrome	372
Biomarkers of pain	372
Biomarkers of neuropathic pain	372
Brain insular glutamate as biomarker of fibromyalgia	373
Biomarkers of visceral pain	373
Biomarkers of migraine	374
Biomarkers of myalgic encephalomyelitis/chronic fatigue syndrome	374
Biomarkers of psychiatric disorders	374
Anorexia nervosa	374
Attention-deficit hyperactivity disorder	375
Biomarkers for autism	375

Biomarkers of depression	376
Biomarkers of psychosis	376
Biomarkers of schizophrenia	377
<i>Biomarkers of abnormalities of visual information processing</i>	377
<i>Genetic biomarkers of schizophrenia</i>	377
<i>Gene expression analysis of blood for biomarkers of schizophrenia</i>	377
<i>Metabolic biomarkers of schizophrenia</i>	378
<i>Proteomic studies for biomarkers of schizophrenia</i>	378
8. Biomarkers of Cardiovascular Disorders	379
Introduction.....	379
Epidemiology of cardiovascular disease	379
Biomarkers of cardiovascular diseases	379
Biomarkers of acute myocardial infarction	381
Genetic biomarkers of cardiovascular disorders	381
Methods for identification of cardiovascular biomarkers.....	383
Application of proteomics for biomarkers of cardiovascular disease.....	383
<i>Targeted MS-based pipeline approach</i>	383
<i>Cardiovascular disease biomarker panel</i>	383
Detection of biomarkers of myocardial infarction in saliva by a nanobiochip.....	384
Metabolomic technologies for biomarkers of myocardial ischemia	384
Imaging biomarkers of cardiovascular disease	384
<i>Annexin A5 as an imaging biomarker of cardiovascular disease</i>	385
<i>Cardiovascular MRI</i>	385
<i>Myocardial perfusion imaging</i>	385
Applications of biomarkers of cardiovascular disease.....	385
Biomarkers for ischemic heart disease and myocardial infarction.....	386
<i>Troponin</i>	386
<i>Natriuretic peptide</i>	387
<i>Copeptin</i>	389
<i>Creatine kinase muscle brain</i>	389
<i>miRNAs as biomarkers of acute coronary syndrome</i>	389
<i>Myoglobin</i>	389
<i>Fatty acid binding protein</i>	389
<i>Growth Differentiation Factor-15</i>	390
<i>High density lipoprotein 2</i>	390
<i>Cripto-1 as a biomarker of myocardial infarction</i>	390
<i>Cataract as a biomarker of ischemic heart disease</i>	390
<i>Plasma CD93 as a biomarker for coronary artery disease</i>	391
<i>Plasma fetuin-A levels and the risk of myocardial infarction</i>	391
Biomarkers of congestive heart failure	391
<i>Angiogenesis biomarkers</i>	391
<i>beta-2a protein as a biomarker of heart failure</i>	392
<i>Desmin</i>	392
<i>Galectin-3 as biomarker of acute heart failure</i>	392
<i>G protein-coupled receptor kinase-2 as biomarker of CHF</i>	392
<i>KIF6 gene as biomarker of CHF</i>	393
<i>NT ProBNP as biomarker of CHF</i>	393
<i>Oxidative stress as biomarker of heart failure</i>	394
<i>Future prospects for biomarkers of heart failure</i>	394
Biomarkers for atherosclerosis.....	394
<i>Adipocyte enhancer-binding protein 1</i>	395
<i>Gene signatures on leucocytes as biomarkers of atherosclerosis</i>	395
<i>Ghrelin as a biomarker of atherosclerosis</i>	395
<i>Imaging biomarkers of hypercholesterolemia/atherosclerosis</i>	396
<i>Inflammatory biomarkers of atherosclerosis</i>	396
<i>Lipid-modified proteins as biomarkers of atherosclerosis</i>	396
<i>Lp-PLA2 as biomarker of atherosclerotic heart disease</i>	397
<i>Nitric oxide impairment and atherosclerosis</i>	397
<i>Oxygen free radicals as biomarkers of atherosclerosis</i>	397
<i>Proteomic profiles of serum inflammatory markers of atherosclerosis</i>	397
Biomarkers of risk factors for coronary heart disease.....	398
<i>Antibody to oxidized-LDL</i>	398
<i>Apolipoproteins as risk factors for coronary heart disease</i>	398
<i>CRP as biomarker of risk for coronary heart disease</i>	398
<i>Impairment of EPCs by oxidative stress as a biomarker of disease</i>	399
<i>Role of TNF in acute coronary syndromes</i>	399
Biomarkers for pulmonary arterial hypertension.....	400
<i>Biomarkers of abdominal aortic aneurysm</i>	400
Genetic biomarkers for cardiovascular disease	401
<i>Biomarkers of inherited cardiomyopathies</i>	401

<i>Gene mutations in pulmonary arterial hypertension</i>	401
<i>Gene variant as a risk factor for sudden cardiac death</i>	402
<i>Genetic biomarkers of early onset myocardial infarction</i>	402
<i>Genetic biomarkers of atherosclerosis</i>	402
<i>IL-1 gene polymorphism as biomarker of cardiovascular disease</i>	403
<i>Kallikrein gene mutations in cardiovascular disease</i>	403
<i>Kallikrein gene and essential hypertension</i>	403
<i>Mutations in the low density lipoprotein receptor gene</i>	404
<i>Mutations within several genes that code for ion channel</i>	404
<i>Polymorphisms of the eNOS gene and angina pectoris</i>	404
<i>Polymorphisms in the apolipoprotein E gene</i>	405
<i>Polymorphism in the angiotensinogen gene</i>	405
Multiple biomarkers for prediction of death from cardiovascular disease	405
Role of biomarkers in the management of cardiovascular disease	406
Biomarkers in the diagnosis/prognosis of myocardial infarction	406
Biomarkers for prevention of cardiovascular disease	406
C-reactive protein as biomarker of response to statin therapy	407
Molecular signature analysis in management of cardiovascular diseases	408
Role of circulating biomarkers and mediators of cardiovascular dysfunction	408
Use of protein biomarkers for monitoring acute coronary syndromes	408
Use of biomarkers for prognosis of recurrent atrial fibrillation	409
Use of multiple biomarkers for monitoring of cardiovascular disease	409
Use of biomarkers in the management of peripheral arterial disease	410
Use of biomarkers in the management of hypertension	410
Future prospects for cardiovascular biomarkers	410
Cardiovascular Biomarker Consortium	410
Systems Approach to Biomarker Research in Cardiovascular Disease	411
9. Biomarkers & Personalized Medicine	413
Introduction	413
Pharmacogenetics	413
Biomarkers and pharmacogenetics	414
Pharmacogenomics	415
Pharmacoproteomics	416
Single cell proteomics for personalized medicine	416
Role of biomarkers in development of personalized drugs	417
Use of biomarkers for developing MAb therapy in oncology	417
Biobanking, biomarkers and personalized medicine in EU	417
Expression signatures as diagnostic/prognostic tools	418
Biomarkers for monitoring response to therapy	418
Drug rescue by biomarker-based personalized medicine	419
Future role of biomarkers in personalized medicine	419
10. Regulatory issues	421
Introduction	421
Biomarker validation	421
FDA criteria for a valid biomarker	421
Role of NIST in validation of cancer biomarkers	423
Quality specifications for BNP and NT-proBNP as cardiac biomarker assays	423
FDA perspective of biomarkers in clinical trials	424
FDA and predictive medicine	425
Biomarkers and FDA's Voluntary Genomic Data Submission	426
Role of imaging biomarkers in approval of drugs	426
FDA Critical Path Initiative and biomarker R&D	427
FDA consortium linking genetic biomarkers to serious adverse events	427
Oncology Biomarker Qualification Initiative	428
Critical Path Initiative	429
<i>Predictive Safety Testing Consortium</i>	430
From validated biomarker assay to a clinical laboratory diagnostic	430
Fast Path programs	431
Need for a single federal agency to oversee biomarker field	431
11. Markets for Biomarkers	433
Introduction	433
Biomarker markets according to technologies/applications	433
Markets for protein biomarkers	433
Biomarker market relevant to drug discovery and development	434
Biomarker market relevant to epigenetics	434
Biomarker market relevant to bioinformatics	434
Biomarker markets according to therapeutic areas	434
Geographical distribution of biomarker markets	435

Unfulfilled needs in biomarkers	435
Drivers for the growth of markets for biomarkers	436
Challenges facing the biomarker industry	437
Pitfalls in the discovery and development of biomarkers.....	437
Strategies for developing biomarker markets	437
Utilization of biomarker research in academic laboratories.....	438
Biomarker discovery at pharmaceutical companies.....	438
Industrial-academic collaborations in biomarkers	438
Application of biomarkers in medical practice.....	439
<i>Future role of biomarkers in healthcare.....</i>	<i>439</i>
Applications of biomarkers beyond healthcare	440
<i>Combating bioterrorism</i>	<i>440</i>
<i>Biomarkers for monitoring human exposure to environmental toxins</i>	<i>440</i>
<i>Application of biomarkers in animal health</i>	<i>441</i>
Biomarker patents	441
Factors that enhance the value of biomarker IP	442
US policy on gene patenting relevant to biomarkers	442
<i>US legal decisions on gene patenting</i>	<i>443</i>

12. References..... 445

Tables

Table 1-1: Historical landmarks in discovery and development of biomarkers	24
Table 1-2: Classification of biomarkers	24
Table 1-3: Terminology of biomarkers of disease relevant to clinical development.....	26
Table 1-4: Autoimmune disorders under study for autoantibodies as predictors	35
Table 1-5: Comparison of various types of biomarkers	35
Table 1-6: Use of “-omic” technologies for discovery of biomarkers.....	37
Table 1-7: Role of biomarkers in translational medicine	38
Table 2-1: Classification of methods of gene expression analysis	42
Table 2-2: Comparison of proteomic profiling technologies for discovery of biomarkers	63
Table 2-3: Companies involved in developing molecular imaging	72
Table 3-1: Applications of biochip/microarray technology in relation to biomarkers	93
Table 4-1: Companies using metabolomics for drug discovery	100
Table 4-2: Causes of failures in clinical trials and their reduction by use of biomarkers	113
Table 4-3: Biomarker-based drug development at major pharmaceutical companies	114
Table 5-1: Biomarkers of diabetes mellitus	124
Table 5-2: miRNAs deregulated in rheumatoid arthritic tissues	135
Table 5-3: Biomarkers of sepsis.....	140
Table 5-4: Biomarkers of pulmonary diseases	156
Table 5-5: Biomarkers of aging	172
Table 5-6: Examples of biomarkers common to multiple diseases	179
Table 6-1: Desirable characteristics of biomarkers for cancer	185
Table 6-2: Types of cancer biomarkers	186
Table 6-3: A classification of molecular diagnostic methods in cancer	190
Table 6-4: Novel biomarkers of prognosis in cancer treatment.....	223
Table 6-5: Biomarkers of brain tumors	230
Table 6-6: Biomarkers of breast cancer	237
Table 6-7: miRNA associated with breast cancer	245
Table 6-8: Biomarkers of colorectal cancer.....	256
Table 6-9: Biomarkers of lung cancer	268
Table 6-10: Classification of biomarkers of melanoma	275
Table 6-11: Biomarkers of nasopharyngeal carcinoma and potential applications	277
Table 6-12: Biomarkers of ovarian cancer	280
Table 6-13: Classification of biomarkers of pancreatic cancer	284
Table 6-14: Biomarkers of prostate cancer.....	288
Table 7-1: Biomarkers of cerebral metabolism	311
Table 7-2: Classification of biochemical markers of AD in blood and CSF.....	320
Table 7-3: Characteristics of an ideal biomarker for Alzheimer disease	322
Table 7-4: Biomarkers of Parkinson’s disease	339
Table 7-5: Biomarkers of Huntington disease	343
Table 7-6: Classification of biomarkers of sporadic amyotrophic lateral sclerosis.....	344
Table 7-7: Biomarkers of multiple sclerosis	349
Table 7-8: Biomarkers of response to interferon- β in multiple sclerosis.....	353
Table 7-9: Biomarkers of stroke	355
Table 7-10: Biochemical biomarkers of traumatic brain injury.....	362
Table 7-11: Biomarkers of traumatic brain injury	364
Table 7-12: Biomarkers of epilepsy	368
Table 8-1: Classification of biomarkers for cardiovascular diseases.....	380

Table 8-2: Genes that cause cardiovascular diseases.....	382
Table 9-1: Pharmacogenetic vs. pharmacogenomic studies	414
Table 9-2: Applications of pharmacoproteomic biomarkers in personalized medicine	416
Table 11-1: Biomarker markets according to technologies/applications 2011-2021	433
Table 11-2: Biomarker markets according to therapeutic areas 2011-2021	435
Table 11-3: Geographical distribution of biomarker markets 2011-2021	435
Table 11-4: Factors driving the growth of biomarker industry	436

Figures

Figure 1-1: Relation of biomarkers to other technologies and healthcare.....	38
Figure 2-1: The central role of spectrometry in proteomics	50
Figure 4-1: Role of biomarkers in drug discovery and development process	97
Figure 6-1: Role of proteomics in the discovery of cancer biomarkers.....	198
Figure 6-2: Cancer biomarker development and validation.....	305
Figure 7-1: Discovery and application of biomarkers in neurological diseases	309
Figure 8-1: Biomarkers of acute myocardial infarction related to pathophysiology.....	381
Figure 9-1: Role of pharmacogenetic biomarkers in personalized medicine.....	415
Figure 9-2: Impact of biomarkers on personalized medicine	420
Figure 10-1: Stages and timelines of biomarker discovery, development and marketing	421
Figure 10-2: Biomarker qualification pilot process at the FDA	423
Figure 10-3: From a validated biomarker assay to a clinical laboratory diagnostic	431
Figure 11-1: Unfulfilled needs in biomarkers technologies and applications	436